Abbvie Inc represents values of innovation, integrity, and a patient-centric approach. With a corporate philosophy focused on discovering and delivering advanced solutions, Abbvie strives to make a remarkable impact on people's lives. The company is committed to advancing science and developing breakthrough treatments in various therapeutic areas, including immunology, oncology, and neuroscience. Abbvie's dedication to excellence and its emphasis on collaboration and ethical practices enable the company to provide transformative healthcare solutions for patients worldwide.

Abbvie Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with a focus on key markets such as the United States, Europe, Asia Pacific, and Latin America. Abbvie Inc operates in multiple countries, including the United Kingdom, Germany, France, Italy, Japan, China, Australia, Brazil, and Mexico, among others. With their international reach, Abbvie Inc continues to expand its business operations and leverage opportunities in different markets to serve a diverse customer base.

Abbvie Inc, a leading pharmaceutical company, has achieved several significant milestones. In 2013, the company was spun off from Abbott Laboratories, marking a significant step towards establishing its independent identity. Abbvie has also made remarkable progress in the development of innovative therapies. Notably, their drug Humira became a game-changer, becoming the world's best-selling medicine and achieving several regulatory approvals for multiple indications. In addition, Abbvie has expanded its pipeline with the successful launch of new products like Skyrizi and Rinvoq, further strengthening its position in the industry. These accomplishments highlight Abbvie Inc's commitment to advancing healthcare and improving patient outcomes.

Abbvie Inc is a pharmaceutical company with a rich history and background. It was established in 2013 as a spin-off from Abbott Laboratories. Abbvie focuses on researching, developing, and manufacturing innovative drugs to address various health conditions. With headquarters in North Chicago, Illinois, Abbvie operates on a global scale, delivering advanced therapies to patients worldwide. The company is renowned for its expertise in immunology, oncology, neuroscience, and virology areas. Abbvie has a diverse portfolio of products, including popular brands such as Humira, Imbruvica, and Venclexta, which have positively impacted millions of lives. With a commitment to advancing science and improving patient outcomes, Abbvie continues to make significant contributions to the healthcare industry.

The main competitors of Abbvie Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Bristol-Myers Squibb Company.

Abbvie Inc is primarily active in the pharmaceutical industry.

The business model of Abbvie Inc is focused on research, development, and commercialization of innovative pharmaceutical products. Abbvie specializes in the discovery and production of drugs primarily in the fields of immunology, oncology, and neuroscience. The company aims to provide effective therapies for various medical conditions, improving the quality of life for patients worldwide. With a strong focus on research and development, Abbvie strives to bring new treatments to market and address unmet medical needs. Through strategic partnerships and collaborations, Abbvie ensures a diversified product portfolio and maintains its position as a leading pharmaceutical company.

AbbVie의 P/E 비율은 17.48입니다.

AbbVie의 P/S 비율은 6.04입니다.

AbbVie에 대한 AlleAktien 품질 점수는 10/10입니다.

예상되는 AbbVie 매출은 56.8 조. USD입니다.

예상되는 AbbVie 이익은 19.61 조. USD입니다.

Abbvie Inc. is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for some of the world's most serious diseases. This primarily includes oncology, immunological disorders, neurodegenerative diseases, skin diseases, viral and bacterial infections, eye diseases, and metabolic disorders. Abbvie has been an independent company since 2013, following a spin-off from Abbott Laboratories. The company is headquartered in North Chicago, Illinois, USA, and employs over 30,000 people worldwide. Abbvie has four main business segments: 1. Immunology: Approximately 60 percent of Abbvie's revenue comes from the immunology division. The company specializes in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis. Key products in the immunology division include Humira, Rinvoq, SkyRizi, and Skyrizi. 2. Hematology and Oncology: Abbvie also has a strong presence in the field of hematology and oncology. Leading products in this segment include Venclexta, Imbruvica, and Mavyret. 3. Neurology: Abbvie also offers products in the field of neurology, such as Skyrizi, Botox, Azelex, and Tazorac. 4. Aesthetic Medicine: The company offers products like Juvederm and Botox in this segment. Abbvie invests heavily in research and development to discover innovative therapies that can improve the lives of patients worldwide. The company has a strong portfolio of patents and prioritizes comprehensive clinical testing in the development of new products to ensure high quality and efficacy. Additionally, the company has formed several collaborative partnerships to accelerate its research and development in various areas. For example, Abbvie has partnered with Biogen in the development of drugs for multiple sclerosis and has cooperated with Alector in the field of neurodegenerative diseases. Abbvie continues to delight its customers with valuable products and services, thereby expanding its leading position in the biopharmaceutical industry. In summary, Abbvie is an innovative and rapidly growing company that plays an important role in the global biopharmaceutical market through its top-notch products and investments in research and development.

AbbVie은(는) 연간 4번의 배당을 통해 5.64 USD의 배당금을 지급합니다.

AbbVie는 연간 4번의 배당금을 지급합니다.

AbbVie의 ISIN은 US00287Y1091입니다.

AbbVie의 WKN은 A1J84E입니다.

AbbVie의 티커는 ABBV입니다.

지난 12개월 동안 AbbVie은(는) 5.92 USD 의 배당금을 지급했습니다. 이는 약 3.06 %의 배당 수익률에 해당합니다. 향후 12개월 동안 AbbVie은(는) 6.04 USD의 배당금을 지급할 것으로 예상됩니다.

AbbVie의 현재 배당 수익률은 3.06 %입니다.

AbbVie은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

AbbVie은(는) 지난 101년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 6.04 USD의 배당금이 예상됩니다. 이는 배당수익률 3.12 %에 해당합니다.

AbbVie은 '건강' 섹터에 속합니다.

AbbVie의 마지막 배당금을 1.55 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 AbbVie는 5.64 USD를 배당금으로 지급했습니다.

AbbVie의 배당금은 USD에 지급됩니다.